

## PainChek Reports Strong Quarterly Sales Growth

**Sydney, Australia, 3 July 2025** – PainChek Ltd (ASX: PCK) ("PainChek" or "the Company"), developer of the world's first smart device-based pain assessment and monitoring application, is pleased to provide a sales update for the quarter ended 30 June 2025.

### Highlights:

- Net Contracted Licences increased 9% to 110,000.
- Contracted Annual Recurring Revenue (ARR) up 10% to A\$5.4 million.
- Net Licence Retention rate at 106%, highlighting customer expansion.
- New clients secured across the UK, Australia, and Canada with a mix of 1 and 2-year agreements.
- New agreements based on fixed implementation and billing.
- Global pain assessments exceed 12 million.
- Scottish Inspectorate validation study reports positive outcomes.

PainChek's robust growth in contracted licences and recurring revenue underscores continued strong demand and acceptance of the Company's innovative pain assessment technology within the aged care sector. The increase in licences and ARR is attributed to successful expansion strategies and new customer acquisitions across diverse geographical markets.

This includes new clients in key regions including the United Kingdom, Australia, and Canada, covering a broad spectrum of residential aged care groups from small to large-scale providers and a mix of 1 year and 2 year terms. This diversification demonstrates the broad applicability and scalable nature of PainChek's platform.

The achievement of over 12 million global pain assessments highlights the strong and growing clinical utility of PainChek's technology, and its effectiveness in improving patient outcomes and supporting clinical decision-making.

Further endorsement comes from the Scottish Inspectorate's validation study, which has produced positive outcomes, positioning PainChek strategically within the Scottish Government's aged care strategy review. The next step involves a comprehensive cost-benefit analysis, indicating strong potential for further adoption and integration into national healthcare frameworks.

PainChek CEO Philip Daffas said: "We're very pleased to see the continued uptake and benefit being derived from the PainChek technology, especially as our footprint grows in key overseas markets such as the UK and Canada. New agreements have pre-determined subscription activation and billing dates based on size of the client and agreed roll out schedule. With a strong sales pipeline in existing markets, new

products and geographies expected to come online in the near term, the Company is well set up for substantial growth looking ahead.”

This announcement has been approved for release by the Board.

For more information:

Natalie Climo  
Company Secretary, PainChek  
[natalie.climo@boardroomlimited.com.au](mailto:natalie.climo@boardroomlimited.com.au)  
02 8016 2875

Philip Daffas  
CEO, PainChek  
[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)  
0406 537 235

### About PainChek

[PainChek®](#) is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,800 aged care facilities, with more than 12,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer’s Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>